Recovery and survival of platelets in additive solutio

• Conditions: Hemato oncologic disease; myelodysplastic syndrome; platelets; plasma; additive solution; recovery; survival

• Registration Number: NL-OMON24088
• Lead Sponsor: Sanquin Bloedbank

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Other
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

• Age ≥ 18 years.

• Expected to require at least one platelet transfusion.

Exclusion Criteria

• Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP.

• Bleeding  grade 2 at time of inclusion.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Platelet recovery in the study groups should be &#8805;67% of platelets in plasma stored for 2-3 <br><br>days.

Secondary Outcome Measures

Name	Time	Method
o Phase 2: To determine the recovery and survival of platelet concentrates in Composol, <br><br>Intersol and SSP+ (in a ±35%-plasma/±65%-PAS ratio) stored for 6-7 days. <br /><br><br>o To determine survival of platelet concentrates, stored for 2-3 (plasma only) or 6-7 days in <br><br>plasma, Composol, Intersol and SSP+ (in a ±35%-plasma/±65%-PAS ratio).<br><br /><br>o To determine the 1-h and 24-h count increment and corrected count increment of platelet <br><br>concentrates, stored for 2-3 (plasma only) or 6-7 days in plasma, or in Composol, Intersol and <br><br>SSP+ (in a ±35%-plasma/±65%-PAS ratio).